<DOC>
	<DOCNO>NCT00752427</DOCNO>
	<brief_summary>The purpose open-label study evaluate safety tolerability flexible dos Extended Release OROS® Paliperidone treatment geriatric subject schizophrenia completion initial double blind study</brief_summary>
	<brief_title>24-Week Open Label Extension Randomized , 6-Week Double Blind , Placebo Controlled Study , Evaluate Safety Tolerability Flexible Doses Extended Release OROS® Paliperidone Treatment Geriatric Subjects With Schizophrenia</brief_title>
	<detailed_description>The primary objective open-label extension phase long-term assessment safety tolerability Extended Release ( ER ) OROS paliperidone ( 3 mg 12 mg/day ) subject ( &gt; 65 year age ) schizophrenia , secondary objective assessment long-term efficacy . Paliperidone ER OROS® tablet formulation ( 3 12 mg/day ) take orally</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Subjects complete doubleblind phase discontinue due lack efficacy least 21 day treatment , sign informed consent openlabel phase , investigator agree openlabel treatment best interest subject eligible participate open label phase Significant and/or unstable systemic illness Allergy hypersensitivity risperidone paliperidone Significant risk suicidal violent behavior Biochemistry , hematology , urinalysis result within laboratory 's reference range , deem investigator clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia : paliperidone</keyword>
</DOC>